MARKET

CYCC

CYCC

Cyclacel Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.420
+0.110
+2.55%
Opening 12:33 08/14 EDT
OPEN
4.370
PREV CLOSE
4.310
HIGH
4.440
LOW
4.270
VOLUME
239.06K
TURNOVER
--
52 WEEK HIGH
19.60
52 WEEK LOW
3.850
MARKET CAP
21.48M
P/E (TTM)
-0.0257
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CYCC stock price target is 21.33 with a high estimate of 24.00 and a low estimate of 18.00.

EPS

CYCC News

More
Cyclacel Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 EPS results.
Benzinga · 1d ago
The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 1d ago
Cyclacel Pharmaceuticals Q2 EPS $(0.58) Misses $(0.47) Estimate
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.47) by 23.4 percent. This is a 72.77 percent increase over losses of $(2.13) per
Benzinga · 1d ago
Cyclacel Pharmaceuticals EPS misses by $1.66
Cyclacel Pharmaceuticals (CYCC): Q2 GAAP EPS of -$2.13 misses by $1.66.Shares -6.8%.Press Release
Seekingalpha · 1d ago
Cyclacel Pharmaceuticals EPS misses by $1.66
Cyclacel Pharmaceuticals (CYCC): Q2 GAAP EPS of -$2.13 misses by $1.66.Shares -6.8%.Press Release
Seekingalpha · 1d ago
Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second
GlobeNewswire · 08/05 11:00
Cyclacel (CYCC) to Report Q2 Earnings: What's in the Offing?
Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.
Zacks · 07/28 15:46
Edited Transcript of CYCC.OQ earnings conference call or presentation 12-May-20 8:30pm GMT
Q1 2020 Cyclacel Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents · 07/23 05:51

Industry

Biotechnology & Medical Research
-0.58%
Pharmaceuticals & Medical Research
-0.29%

Hot Stocks

Symbol
Price
%Change

About CYCC

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
More

Webull offers kinds of Cyclacel Pharmaceuticals Inc stock information, including NASDAQ:CYCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYCC stock methods without spending real money on the virtual paper trading platform.